Lucentis (ranibizumab) is now Pharmaceutical Benefits Scheme (PBS) reimbursed for proliferative diabetic retinopathy (PDR) in adults.1
The anti-VEGF therapy has long been listed on the PBS for diabetic macular oedema (DMO).
An announcement from Novartis to Australian ophthalmologists said that for PDR patients, PBS authority approval requires a documented retinal image confirming proliferative disease (no visual acuity restriction).
Existing PBS requirements for DMO remain in place, requiring evidence of macular oedema on optical coherence tomography or fundus fluorescein angiography imaging and a baseline visual acuity between 20/32 and 20/160 in the eye to be treated.
PBS Information |
|---|
| Authority required for the treatment of wet AMD, DMO, BRVO, CRVO, PDR, PM or for the treatment of CNV secondary to causes other than wet AMD and PM. Refer to PBS Schedule for full Authority information. This product is not PBS listed for the treatment of ROP.
Lucentis PBS information is available online: pre-filled syringe or vial for injection. |
References
- Pharmaceutical Benefits Scheme Website – Lucentis listing and criteria (accessed Sep 2025).
- Lucentis (ranibizumab) Approved Product Information.
